Ruxolitinib: a targeted treatment option for patients with polycythemia vera.

111 There was a nonsignificant trend toward a greater improvement in the MPN-SAF cytokine cluster TSS (TSS-C) with ruxolitinib compared with hydroxyurea (proportion of patients achieving ≥50% reduction from baseline in TSS-C at Week 16: 43.4% vs 29.6%, respectively; primary endpoint). 111 Additionally, there was a nonsignificant trend

also in 5,406 other papers